Mechanisms of cancer cell metastasis to the bone: A multistep process

Future Oncology

Volumn 7, Issue 11, 2011, Pages 1285-1297

  Patel, Lalit R ^a   Camacho, Daniel F ^a   Shiozawa, Yusuke ^b   Pienta, Kenneth J ^a   Taichman, Russell S ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

Author keywords

anoikis; autophagy; circulating tumor cells; disseminated tumor cells; dormancy; metastasis; osteoblastogenesis; osteolysis; survival

Indexed keywords

BONE DEVELOPMENT; BONE METASTASIS; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL ADHESION; CELL CLONE; CELL DEATH; CELL DIFFERENTIATION; CELL HOMING; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; DORMANCY; EXTRACELLULAR MATRIX; HUMAN; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR SEEDING;

BONE MARROW; BONE NEOPLASMS; BREAST NEOPLASMS; CELL ADHESION; CHEMOKINES; EXTRACELLULAR MATRIX; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS;

EID: 80455174397     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.112     Document Type: Review

References (62)

1. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br. J. Cancer 55(1), 61-66 (1987). (Pubitemid 17234155)
2. Gralow JR, Biermann JS, Farooki A et al. NCCN Task Force Report: bone health in cancer care. J. Natl Compr. Canc. Netw. 7(Suppl. 3), S1-S32 (2009).
3. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27(3), 165-176 (2001). (Pubitemid 32452017)
4. Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007).J. Urol. 184(1), 162-167 (2010).
5. Pienta KJ, Loberg R. The "emigration, migration, and immigration"of prostate cancer. Clin. Prostate Cancer 4(1), 24-30 (2005). (Pubitemid 41018179)
6. Roodman GD. Mechanisms of bone metastasis. N. Engl. J. Med. 350(16), 1655-1664 (2004).
7. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 66(1), 1-9 (2008). (Pubitemid 351324128)
8. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706), 58-62 (2005). (Pubitemid 40093472)
9. Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim. Biophys. Acta 1032(1), 89-118 (1990).
10. Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin. Cancer Res. 7(3), 462-468 (2001). (Pubitemid 32707965)
11. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat. Rev. Genet. 8(5), 341-352 (2007). (Pubitemid 46625811)
12. Rodenhiser DI. Epigenetic contributions to cancer metastasis. Clin. Exp. Metastasis 26(1), 5-18 (2009).
13. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 66(1), 1-9 (2008). (Pubitemid 351324128)
14. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 28(1-2), 15-33 (2009).
15. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev. Cancer 2(4), 277-288 (2002). (Pubitemid 37328781)
16. Woods NT, Yamaguchi H, Lee FY, Bhalla KN, Wang HG. Anoikis, initiated by Mcl 1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Res. 67(22), 10744-10752 (2007). (Pubitemid 350145901)
17. Mawji IA, Simpson CD, Hurren R et al. Critical role for Fas-associated death domain-like interleukin 1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation. J. Natl Cancer Inst. 99(10), 811-822 (2007). (Pubitemid 47073526)
18. Codogno P, Meijer AJ. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ. 12(Suppl. 2), 1509-1518 (2005). (Pubitemid 41553987)
19. Roca H, Varsos ZS, Mizutani K, Pienta KJ. CCL2, survivin and autophagy: new links with implications in human cancer. Autophagy 4(7), 969-971 (2008).
20. He W, Kularatne SA, Kalli KR et al. Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands. Int. J. Cancer 123(8), 1968-1973 (2008).
21. Ewing J. Neoplastic Diseases: A Treatise on Tumors. WB Saunders Co., Philadelphia & London (1928).
22. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 133(3421), 571-573 (1889).
23. Salcedo R, Oppenheim JJ. Role of chemokines in angiogenesis: CXCL12/SDF 1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 10(3-4), 359-370 (2003). (Pubitemid 39004262)
24. Broxmeyer HE, Orschell CM, Clapp DW et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 201(8), 1307-1318 (2005). (Pubitemid 40629073)
25. Wang J, Shiozawa Y, Wang Y et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF 1 in prostate cancer. J. Biol. Chem. 283(7), 4283-4294 (2008).
26. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor 1/ CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 62(6), 1832-1837 (2002). (Pubitemid 34408510)
27. Schneider JG, Amend SR, Weilbaecher KN. Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone 48(1), 54-65 (2011).
28. Giancotti FG, Ruoslahti E. Integrin signaling. Science 285(5430), 1028-1032 (1999).
29. Santagata S, Demichelis F, Riva A et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res. 64(19), 6854-6857 (2004). (Pubitemid 39330990)
30. Chiba S. Notch signaling in stem cell systems. Stem Cells 24(11), 2437-2447 (2006). (Pubitemid 44674304)
31. Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 19(2), 192-205 (2011).
32. Shiozawa Y, Havens AM, Jung Y et al. Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J. Cell. Biochem. 105(2), 370-380 (2008).
33. Shiozawa Y, Pedersen EA, Havens AM et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 121(4), 1298-1312 (2011).
34. Janni W, Vogl FD, Wiedswang G et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse - a European pooled analysis. Clin. Cancer Res. 17(9), 2967-2976 (2011).
35. Morgan TM, Lange PH, Porter MP et al. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin. Cancer Res. 15(2), 677-683 (2009).
36. Abouassaly R, Paciorek A, Ryan CJ, Carroll PR, Klein EA. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE. Cancer 115(19), 4470-4476 (2009).
37. Vessella RL, Pantel K, Mohla S. Tumor cell dormancy: an NCI workshop report. Cancer Biol. Ther. 6(9), 1496-1504 (2007). (Pubitemid 351590364)
38. Shiozawa Y, Pedersen EA, Patel LR et al. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 12(2), 116-127 (2010).
39. Ding Z, Wu CJ, Chu GC et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470(7333), 269-273 (2011).
40. Moharita AL, Taborga M, Corcoran KE, Bryan M, Patel PS, Rameshwar P. SDF 1a regulation in breast cancer cells contacting bone marrow stroma is critical for normal hematopoiesis. Blood 108(10), 3245-3252 (2006).
41. Lim PK, Bliss SA, Patel SA et al. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res. 71(5), 1550-1560 (2011).
42. Ranganathan AC, Adam AP, Zhang L, Aguirre-Ghiso JA. Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells? Cancer Biol. Ther. 5(7), 729-735 (2006). (Pubitemid 44775124)
43. Horak CE, Lee JH, Marshall JC, Shreeve SM, Steeg PS. The role of metastasis suppressor genes in metastatic dormancy. APMIS 116(7-8), 586-601 (2008).
44. Wikman H, Vessella R, Pantel K. Cancer micrometastasis and tumour dormancy. APMIS 116(7-8), 754-770 (2008).
45. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1(2), 149-153 (1995).
46. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5(16), 1779-1787 (2006). (Pubitemid 44435320)
47. Holcomb IN, Grove DI, Kinnunen M et al. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res. 68(14), 5599-5608 (2008).
48. Liu W, Laitinen S, Khan S et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 15(5), 559-565 (2009).
49. Miller GJ, Cygan JM. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J. Urol. 152(5 Pt 2), 1709-1713 (1994). (Pubitemid 24322612)
50. Macintosh CA, Stower M, Reid N, Maitland NJ. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res. 58(1), 23-28 (1998). (Pubitemid 28027710)
51. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev. Cancer 8(10), 755-768 (2008).
52. Tolstoy L. Anna Karenina. John Lane Company, NY, USA (1911).
53. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4(8), 638-649 (2003). (Pubitemid 36917505)
54. Mizutani K, Sud S, Pienta KJ. Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts. J. Cell. Biochem. 106(4), 563-569 (2009).
55. Miossec P, Korn T, Kuchroo VK. Interleukin 17 and type 17 helper T cells. N. Engl. J. Med. 361(9), 888-898 (2009).
56. Tan W, Zhang W, Strasner A et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470(7335), 548-553 (2011).
57. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer 5(1), 21-28 (2005). (Pubitemid 40052322)
58. Behrens J, Von Kries JP, Kuhl M et al. Functional interaction of b catenin with the transcription factor LEF 1 Nature 382(6592), 638-642 (1996). (Pubitemid 26268958)
59. Qiang YW, Hu B, Chen Y et al. Bortezomib induces osteoblast differentiation via Wnt-independent activation of b catenin/TCF signaling. Blood 113(18), 4319-4330 (2009).
60. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39(4), 246-261 (1999). (Pubitemid 29244499)
61. Lin DL, Tarnowski CP, Zhang J et al. Bone metastatic LNCaP-derivative C4 2B prostate cancer cell line mineralizes in vitro. Prostate 47(3), 212-221 (2001). (Pubitemid 32378373)
62. Cheng J, Wu Y, Mohler JL, Ip C. The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction. Cancer Biol. Ther. 9(12), 1033-1042 (2010).